Miethke Marcus, Pieroni Marco, Weber Tilmann, Brönstrup Mark, Hammann Peter, Halby Ludovic, Arimondo Paola B, Glaser Philippe, Aigle Bertrand, Bode Helge B, Moreira Rui, Li Yanyan, Luzhetskyy Andriy, Medema Marnix H, Pernodet Jean-Luc, Stadler Marc, Tormo José Rubén, Genilloud Olga, Truman Andrew W, Weissman Kira J, Takano Eriko, Sabatini Stefano, Stegmann Evi, Brötz-Oesterhelt Heike, Wohlleben Wolfgang, Seemann Myriam, Empting Martin, Hirsch Anna K H, Loretz Brigitta, Lehr Claus-Michael, Titz Alexander, Herrmann Jennifer, Jaeger Timo, Alt Silke, Hesterkamp Thomas, Winterhalter Mathias, Schiefer Andrea, Pfarr Kenneth, Hoerauf Achim, Graz Heather, Graz Michael, Lindvall Mika, Ramurthy Savithri, Karlén Anders, van Dongen Maarten, Petkovic Hrvoje, Keller Andreas, Peyrane Frédéric, Donadio Stefano, Fraisse Laurent, Piddock Laura J V, Gilbert Ian H, Moser Heinz E, Müller Rolf
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - Helmholtz Centre for Infection Research (HZI), and Department of Pharmacy, Saarland University Campus E8.1, Saarbrücken, Germany.
German Center for Infection Research (DZIF), Braunschweig, Germany.
Nat Rev Chem. 2021;5(10):726-749. doi: 10.1038/s41570-021-00313-1. Epub 2021 Aug 19.
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.
对新型抗菌药物的需求不断增加，以治疗由多重耐药细菌病原体全球传播引起的危及生命的感染，这与目前在其开发方面的投资水平形成了鲜明对比，特别是在天然产物衍生和合成小分子领域。全球迫切需要具有创新化学结构和作用模式的新型药物，以应对抗菌药物耐药性带来的公共卫生威胁。在此，我们的联盟提出了一项战略蓝图，以大幅提高我们发现和开发新抗生素的能力。我们提出了短期和长期解决方案，以克服研究和资金各部门最紧迫的限制，旨在弥合学术、产业和政治利益相关者之间的差距，并整合跨学科专业知识，以便有效地推动转化进程，造福子孙后代。
